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I. STATEMENT OF THE PROBLEM 
Glaucomatous optic neuropathy 1s the third leading cause of 
blindness in the United States (1 ). Over the least decade, glaucoma 
has emerged as a "multifactorial" disease which suggest various risk 
factors and etiologies at work. High intraocular pressure is one of the 
most common factors associated with glaucomatous damage however 
its absence dose not rule it out of the diagnosis. It is in these cases 
that normal tension glaucoma must be suspect. 
Normal tension glaucoma is believed to represent at least one sixth of 
all open angle glaucoma cases (6). The etiology of NTG is poorly 
understood and exists as a collection of theories at best. Its diagnosis 
of has been described as "a diagnosis of exclusion" and success 
depends on ruling out other forms of optic neuropathy. 
NTG patients are difficult to treat because all of the standard 
treatment regimes are aimed at reducing the IOP (as in classic 
glaucomatous treatment). A through patient evaluation is required in 
order to choose the most appropriate management options. Recent 
technological advances make such patient evaluation accessible to 
optometrists and other primary care givers. 
A. DESCRIPTION AND CLASSIFICATION OF NTG 
Normal tension glaucoma (NTG) is considered a variant of pnmary 
open angle glaucoma (POAG) It is an open angle optic neuropathy 
consisting of glaucomatous cupping of the optic nerve head with 
corresponding visual field defects and the absence of any 
contributing ocular or retinal disorders. What separates NTG from 
POAG is that the lOP is always within the statistically normal range 
m normal tension glaucoma. The statistically normal range is 
considered between 8-20 mm Hg. 
There has been the suggestion that NTG consists of a collection of 
potentially different glaucomas. Indeed, sub-classifications of NTG do 
exist based on the aspect of the optic disk (5,7). Beyond high- versus 
normal-pressure glaucoma there exist a distinction between 
vasospastic and nonvasospastic glaucoma. Several clinical forms of 
NTG, especially vascular, can be identified. Each of these subgroups 
seems to display a different rate of progression (2). These sub-
groups of vascular glaucomas include: 
1) Focal ischemic NTG (FINTG) 
2) Senile sclerotic NTG (SSNTG) 
3) Myopic NTG 
4) Miscellaneous NTG. It is not possible to easily separate pressure-
dependent from pressure independent types of NTG. However, an 
attempt must be made to reach a reasonable conclusion on the most 
likely factor causmg the optic neuropathy and treatment must be 
developed accordingly. In most cases, it is appropriate to assume that 
pressure lowering will help (8). Further deterioration of the visual 
field is expected in about 50% of eyes with NTG in which intraocular 
pressure IS one of the contributing factors (9) 
Based on our current understanding, glaucomatous optic neuropathy 
Is a multifactorial disease in which combinations of risk factors may 
lead to it in one patient but not in another. 
B. EPIDEMIOLOGY OF LOW TENSION GLAUCOMA 
1. Prevalence and Incidence 
a. Low Tension Glaucoma 
The incidence of LTG is affected by the upper limit of the lOP used, 
the frequency of the lOP measurements, and the degree of 
thoroughness used in the differential diagnosis (5). Values used as 
criterion have varied from 21 to 25. As a result, the higher the 
pressure used to differentiate LTG from open-angle glaucoma, the 
higher the incidence. In the normal Caucasian population, surveys 
illustrate the mean lOP to be 15.6 mm Hg and that 97% have a 
pressure less than 24 mm Hg (5) 
The prevalence of LTG can vary depending on the upper limit of 
"normal" lOP and age . In the Baltimore Eye Survey, 16.7% of 
glaucomatous eyes never had a recorded lOP greater than 21 mm 
Hg(23 ). In patients over the age of 40 who were diagnosed with 
OAG, one-third to one-half were classified as having NTG. A higher 
prevalence was noted in the >40 year-old Japanese population, 
accounting for 2% of the population(9). It has been reported that 
LTG represents about one-sixth of all cases of primary open angle 
glaucoma (POAG) (24). 
Optometrists should be aware that a great number of patients with 
low-tension or normo-tensive glaucoma demonstrate progressive 
optic neuropathy, glaucomatous field defects, and open anterior 
chamber angles without ever having pressures above 21 mm Hg. 
Thus, it is crucial to understand and address the problem efficiently. 
In order to properly utilize new treatment modalities into our scope 
of practice. 
C. RISK FACTORS 
1. General 
Due to the asymptomatic nature of the disease, as many as half of the 
patients with glaucomatous damage may be unaware of their 
condition. Therefore, as eye care professionals we must be fully 
aware of the vanous factors that may affect the incidence and 
severity of the disease. 
a. Age, Sex, Race 
LTG is more likely seen m older individuals above the age of 60. 
However, it has also been reported in younger patients. Some 
studies show that the problem occurs more often in women. There 1s 
no evidence at this time indicating a racial predilection for LTG. 
b. Heredity 
There exists a genetic component to the LTG etiology. The risk for 
those individuals with a family history of LTG is higher. 
2. Systemic 
a. Vascular Problems 
Many investigators note that a vascular pathogenesis plays . a role in 
NTG, theorizing that various vascular abnormalities in the optic nerve 
head or somewhere else in the body may lead to decreased perfusion 
of the optic nerve. Geijssen and Greve showed that 50 percent of the 
patients with NTG have a disturbance of blood flow in the posterior 
pole. They also found a higher percentage of NTG patients (70%) 
with systemic vascular risk factors m comparison to patients with 
HTG (20%) (2). 
Various reports such as the one done by Bechetoille (3), have shown 
a relationship between arterial hypotension and NTG. Early 
observations by Sjogren indicated that low blood pressure was also a 
frequent finding in individuals with LTG (5). Gasser and Flammer 
compared the blood-flow velocity 1n high-tension, normal-tension 
glaucoma, and control groups (5). There were no measurable 
differences m the morphologic findings, but the patients with 
normal-tension glaucoma showeJ a statistically significant decrease 
in capillary blood-cell velocity when compared with the high-tension 
and control subjects. In one study, 125 patients with NTG and POAG 
underwent a complete medical diagnostic examination. It was found 
that 59.3% of those with NTG had low blood pressure as compared to 
11.6% with POAG (4). Color Doppler imaging was used by Butt et al. 
(3) to compare NTG patients to a control group. The results suggest 
that in NTG patients, there is an increased resistance to blood flow in 
the arteries supplying the eye. 
It is important to note low blood pressure as an important risk factor 
in NTG for it may contribute to optic nerve head damage in 
susceptible patients, especially in those individuals with preexisting 
local or systemic problems. The fact that patients with Shy-Drager 
syndrome, who have decreased systemic blood pressure in addition 
to NTG and autonomic dysfunction suggests that factors other than 
lOP may be of importance. The following is a list of a few problems 
associated with NTG: internal carotid artery disease, systemic 
arteriosclerosis, diaberes mellitus, thyroid dysfunction, empty sella 
syndrome, and hematological disorders such as severe anemtas, 
polylcythemia, leukemia, and thrombocytopenia to name a few. 
There appears to be strong evidence that vasospasm may be a key 
factor. The study done by Drance and coworkers suggested that if 
vascular factors play a role m the cause of normal-tension glaucoma, 
then they must be localized or vasospastic (5) Women are affected 
by vasospastic disorders five time more than men (4) and NTG is 
significantly more prevalent in women. 
Hitchings detected peripheral vasospasm m patients with NTG, 
measured by observing the reaction of nailfold capillaries after 
exposure to cold(7). NTG patients also show a slow return to baseline 
finger vasospasm after cold provocation which is similar to the 
behavior of migraine patients (2). 
b. Migraine 
Migraine ts a relatively common vascular disease associated with 
decreased cerebral blood flow. Attacks of migraine cause ischemia of 
the brain, optic nerve, and retina. Optic disc ischemia is considered a 
possible cause of LTG. In a study done by Corbett and associates, 48 
percent of the individuals with NTG had a positive history of classic 
migraines (5). In another study, it was found that the frequency of 
headaches with migrainous symptomology was highest in patients 
with NTG as compared to OAG, ocular hypertension and in normal 
eyes (5). Many authors theorize that there is an association, and not 
necessarily a causal relationship between migraine and LTG. 
3. Ocular 
a. lOP 
A direct relationship exists between the level of pressure and the 
amount of optic nerve cupping and field loss in NTG patients. 
Yamagami and associates used the Humphrey (30-2) ST ATPAC to 
compare lOP and field defects in patients with NTG. Results showed 
that the eyes with higher lOP also had more advanced field damage. 
According to Critchton and coworkers the field loss was greater on 
the side with the higher mean lOP. Asymmetry in lOP also had a 
statistically significant association with asymmetry In visual field 
damage in NTG patients (9). One study discussed the relevance of 
asymmetry of the optic disc size to the level of lOP and showed that 
larger discs may be more vulnerable to rises in lOP (9). Geijssen, on 
the other hand, concluded that diabetes, choroidal sclerosis, 
peripapillary atrophy or venous filling time all had a more significant 
effect on visual field damage in NTG than changes in lOP (9). In 
conclusion, other circulatory factors besides changes in lOP may play 
a part in the development of visual field damage. 
b. Optic Disc Hemorrhage 
Research on the incidence of optic disc hemorrhage indicates that 
there 1s a higher frequency of such hemorrhages in patients with 
NTG as compared to those with OAG. Kitazawa and colleagues (5) 
found optic disc hemorrhage in 20.5% of their patients with NTG. 
They further state that the prevalence of disc hemorrhage is five 
times greater for NTG as compared to OAG patients. More 
investigation needs to be done before we clearly understand the 
prognostic importance of such an association. 
c. Peripapillary Defects 
A few studies suggest that the absence of retinal pigment epithelium 
around the optic disc, often described as chorioscleral crescents, 
occurred more often in patients with NTG. Buus and Anderson 
compared the size and incidence of peripapillary changes in patients 
with NTG and ocular hypertension (5). They found that the average 
and frequency of such crescents was higher in those individuals with 
NTG. In addition, other studies have shown that the location of the 
crescent corresponds to the sector of greatest disc damage (5) 
d. Myopia 
It is postulated that the congenital misalignment of the peripapillary 
tissue layers in the myopic eye can contribute to an increased 
vulnerability to pressure changes. Perkins and Phelps found that 
myopia occurs more often among those with OAG, ocular 
hypertension, and NTG (5). Leighton and Tomlinson showed a higher 
incidence of axial myopia m their patients with NTG as compared 
with those who have chronic OAG (5). Even though other authors 
have not been able to show the correlation between myopia and NTG, 
there some evidence suggesting myopia to be a potential risk 
factor(2). 
C. CLINICAL BACKGROUND OF NTG 
1.N atural History 
The condition of normal tension glaucoma was first described by Von 
Graefe in 1857. It was slow to become accepted as a separate 
condition because its presence contradicts the current understanding 
of the relationship between lOP and optic nerve damage. 
There has been much speculation on the etiology of NTG. One 
proposed mechanism suggest hypersensitivity (abnormal 
susceptibility) of the retinal components of some subjects to normal 
pressures (6). There also exists the view that glaucomatous damage 
occurs during undetected pressure spikes. Some believe it is the 
result of genetically determined atrophy. 
Many studies support the role of vascular dysfunction as the key to 
the pathophysiology of NTG (2,3 ,4,5, 10,11,13, 15). Evidence 
suggesting decreased nerve perfusion due to general vascular risk 
factors and local vascular disruptions is compelling however far from 
being proven. Vascular factors are steadily growing to become the 
second risk factor participating in the genesis of glaucomatous optic 
neuropathy (3 ). 
Given the sub classifications and vanous clinical presentations of 
NTG, many of the above theories could be the causative factor m 
individual cases. 
2. Common signs, symptoms and complications 
Patients in the mild to moderate stages of NTG seldom have any 
symptoms or complaints. In more advanced and severe cases, the 
patients may have complaints of a restricted visual field. 
3. Early detection and prevention 
Since little is known about the etiology of NTG, early detection IS 
extremely difficult. In other forms of POAG, it is the presence of 
increased lOP that raises the index of suspicion and initiates early 
treatment, yet this early diagnostic clue is absent in NTG. It is 
interesting to note that up to one-half of people with glaucoma may 
have lOPs below 22 mg Hg at screening (8). 
Our best tool for early detection is through ocular screenmgs and 
complete periodic visual exams. Unfortunately, detection of NTG does 
not occur until significant damage of the optic nerve head or visual 
field defects are identified. The test with the highest sensitivity for 
the detection of glaucoma 1s optic nerve assessment (1). 
Determination of cup-to-disc ratio, the width of the neuroretinal nm 
and presence of notching can be clues to glaucomatous changes. As 
much as 50% of the optic nerve must be lost before the first visual-
field defect appears and there is a 1.6 to 6-year delay between optic 
nerve changes and detectable field loss usmg either static or dynamic 
field testing. Normal cups change 0.23% a year, but glaucomatous 
cups change 3.4% (18) 
A suspicious optic nerve head and . the absence of ocular 
hypertension should receive an intensive evaluation and a through 
glaucoma work-up as outlined in the following pages. 
II ASSESSMENT AND TREATMENT 
The following pages describes the optometric care appropriate for a 
suspected NTG patient. 
A. DIAGNOSIS OF NORMAL TENSION GLAUCOMA 
1. Initial Glaucoma Evaluation. A comprehensive visual exam should 
be performed as outlined in the AOA guidelines series titled Adult 
Comprehensive Vision exam (22) 
Baseline data should be established for key clinical parameters that 
must be evaluated longitudinally m the proper management of 
glaucoma (1). OAG is traditionally diagnosed based on the findings of 
three general areas. These include raised lOP, characteristic visual 
field defects and optic nerve damage. The presence of any two of 
these signs is accepted as sufficient clinical evidence of OAG. The 
diagnosis of NTG therefore requires both visual field loss and optic 
nerve head damage to support diagnosis. 
The diagnosis of NTG is complicated because of the lack of clinical 
norms and standards of the entities that define the disease. 
Quantification of the optic nerve head is extremely subjective, 
however digital ophthalmoscopy and analysis has rended this less of 
a problem. In addition, visual fields are subjective to considerable 
short- and long- term fluctuations. 
a. Patient History 
I. Ocular History. The patient history should include a thorough 
evaluation of all ocular symptoms and related systems overview. 
The following aspects are of special interest : 
A. previous elevated lOP 
B. family Hx POAG 
C. use of topical or systemic corticosteroids 
D. ocular trauma 
E. ocular inflammatory disease 
2. Careful Medical History 
A complete medical history, including all current medications and 
known medicine intolerance· and allergies, ts essential. Special 
consideration should be given to evaluate any systemic vascular 
abnormalities including but not limited to: 
A. hemodynamic crises. 
B. cardiac disease 
1. acute myocardial infarction 
2. congestive heart failure 
3. angma 
C. peripheral vascular disease (including diabetes mellitus) 
D . hypotension, hypertension and anti-hypertensive therapy 
E. cerebrovascular disease (including athero- or arteriosclerosis) 
F . transient ischemic attacks 
G. m1grame and use of vasoactive agents 
H. blood coagulation and viscosity disorders 
B. OCULAR EXAMINATION 
The following should be included for suspect NTG patients: 
• Visual Acuity: central v1s10n ability should be assessed by 
measuring both corrected and uncorrected distance and/or near 
visual acuity. 
• Pupils: evaluate the presence of APD 
• motilities 
• color vision 
• Biomicroscopy: Evaluation of external ocular health and both the 
anterior and posterior segment should be complete. Take special 
care to asses any signs of ocular trauma, ocular inflammatory 
disease, structural abnormalities or medication toxicity. Anterior 
chamber depth should be estimated. There has been some 
evidence that 60% of NTG patients experience copious perilimbal 
conjuctival aneurysms (signs of oculo-spasm) compared to 13% of 
normals (16). 
• Tonometry: lOP should be measured before pupil dilation and 
gonioscopy. While statisticaly normal, measurements tend to be in 
the upper range of normal. Serial dilation (multiple measures) is 
appropriate in suspect cases of NTG and will provide diurnal 
variation information as well as help to detect the presence of any 
pressure spikes. Large diurnal fluctuations comprise the largest 
number of cases so classified, although not always present (14 ). 
Measurement in supine position may also provide insight (1 ). It is 
strongly suggested to adhere to a strict definition of no recorded 
history of lOP of 22 mg Hg or above to qualify as NTG. 
• Gonioscopy: Careful evaluation of anterior chamber angles in all 
quadrants is essential. Rule out CAG and signs of any damage due 
to trauma. It may be valuable to evaluate angles both before and 
after dilation of pupil (1). It is also important to rule out 
intermittent angle-closure. 
• Optic nerve assessment: Stereoscopic and magnified examination 
through a dilated pupil of the ONH will provide the most useful 
information. Careful observation of optic disc cupping, notching 
and displacement, the degree of pallor of disc tissue, presence of 
disc hemorrhages (sign of oculo-spasm) (2) and any peripapillary 
halo and atrophy (2). There exists some evidence that the optic 
nerve in NTG exhibits different characteristics than POAG and CAG 
(5,7) [see appendix 1] 
• NFL assessment: Stereoscopic and magnified examination under 
red free filter provides maximum visualization (1). It has been 
suggested that serial NFL assessment was found to be more 
sensitive than color disc evaluation in the detection of glaucoma 
(1) 
• Fundus evaluation: Look for signs of any oculovascular disease 
such as retinal sclerosis as well as choroidal sclerosis 
• Fundus Photography: For non-subjective data concerning the 
appearance of the optic nerve head and surrounding tissues. Both 
wide angle and higher magnification photographs are 
recommended. 
• Examination of Visual Fields 
Measurement of threshold levels m areas of the VF likely to be 
affected by glaucomatous damage of the ON should be made by 
perimetry . Again evidence suggests that NTG might exhibit 
different patterns of VF loss than POAG and CAG (4). [see 
appendix 2]. Short wavelength automated perimetry is emergmg 
as an effective method to detect the progression of early 
glaucomatous visual field loss (19,20) however this may prove to 
be an indicator for pressure dependent types of NTG and not 
pressure independent types due to the assumption that high lOP 
causes damage to large axons (especially in blue chromatic 
sensitivity loss) as compared to smaller axon damage assumed to 
occur in NTG (9) . 
C. SUPPLEMENTAL TESTING 
If the aforementioned tests do not provide for differential diagnosis 
there still remams supplemental testing procedures that would 
reveal other etiologies to the optic nerve damage: 
1. Laboratory work-up 
Screen for any signs of vascular abnormalities: 
a.CBC 
b.ESR 
c. cholesterol 
2 . Medical evaluation or consultation 
a. glucose tolerance test 
b. cardiac evaluation, ECG, blood pressures 
c. carotid pulses and presence of bruit 
3. Special Testing. 
a. digital scanning ophthalmoscopy for topography of ONH and NFL 
assessment. Quantify the thickness of the NFL. 
b. scanmng laser angiography (SLA) of peripapillary choroid and 
arteriovenous passage time. 
c. Pulsatile ocular blood flow measurement (POBF). 
d. Doppler Ultrasonography for blood flow velocity of ophthalmic 
artery and central retinal artery. Look for low blood velocity and 
elevated resistive index (17). 
e. Fluorescein angiography (2) 
4. Neurologic Evaluation or consultation. 
required if suspect compressive lesions 
a. skull and optic foramen x-ray films 
b.· CT scan if above structures are abnormal 
c. MRI of sellae, orbit and optic nerve to detect diffuse cerebral 
small-vessel ischemic changes which are found more often in NTG 
patients (3,12). 
2.Follow-up Evaluation: 
The earliest detection of glaucoma may reqmre clinical observation 
of very subtle changes in the appearance of the ON, NFL or VF over 
several years. Repeated evaluation 1s necessary for definitive 
diagnosis. 
Follow-up evaluation of NTG is similar to methods used m the initial 
diagnosis and is extremely important if treatment has already been 
initiated. Methods include: 
• Patient history. Note any change m general health or medications, 
side effects or adverse reactions to therapy and compliance with 
prescribed therapy 
• Visual acuity. Various Forms of treatment as well as advancing 
stages of NTG may affect visual acuity. 
• Blood pressure and pulse. Many glaucoma medications may 
adversely affect blood pressure and heart rate. 
• Biomicroscopy. Examination of all external and anterior/posterior 
chambers is needed to detect adverse reactions to therapy. 
• Tonometry. Continue to monitor any changes in lOP including 
diurnal curves. The immediate effect of therapy designed to lower 
lOP should be closely monitored well. 
• Gonioscopy. This is especially important if intermittant angle 
closure has not been ruled out. 
• Optic nerve and nerve fiber layer assessment. Develope a 
systematic way to examine and record these structures. 
• Fundus photography. To provide for unsubjective record of the 
progression of disease state. 
• Automated perimetry. To detect progressiOn of VISIOn loss. 
• Supplemental testing. Due to evidence supporting a vascular 
eitiology, be aware of any signs of vascular disruption and/or 
dysfunction. 
B. DIFFERENTIAL DIAGNOSIS 
Suspect alternative etiologies to the visual condition if any of the 
following are present: 
• reduced central acuity or fluctuating visJOn 
• dyschromatopsia 
• APD 
• significant disc asymmetry 
• atypical field defect (ex. respective of vertical meridian as well 
as central or cecocentral defects) 
• rapid rate of progression of VF loss 
• pallor beyond cupping (especially nasal) 
• reports of headache or other neurological symptoms 
• pain 
Important conditions to rule out are: 
A. AION (associated with temporal arteritis) 
B. history of hypotensive episodes 
1. MI 
2. cardiac arrest 
3. massive hemorrhage 
4. shock 
C. past acute lOP elevations from uveitis, trauma, steroid use, 
intermittant angle closure, glaucomatocylitic crisis, etc. Rule out 
with history 
D. High lOP masked by medications 
Common medications which might play a role: 
1) digoxin- suppresses aqueous formation by 45% (5). 
2) systemic carbonic anhydrase inhibitors such as 
acetazolamide- suppresses aqueous formation by 50% (5). 
3) a combination of 1 and 2 above- suppression of 65% ( 5). 
4) Beta-blockers (5) 
E. Other medications that affect blood supply: 
1) adrenergic agonists such as epinephrine and dipivefrine 
cause vasoconstriction (21 ). 
F. Compressive intracranial lesions (especially m the anterior 
chiasma! area that produces VF defects and optic atrophy which is 
easily confused with glaucomatous damage.) 
G. congenital (many of these might have associated VF defects). 
Rule out: 
• large physiologic cups 
• hypo plastic discs 
• myopic discs 
• Sectorial optic nerve hypoplasia 
• oblique insertion of ON 
• colobomas 
• optic nerve pits 
• drusen of nerve head 
• hereditary optic nerve pathologies (cupping IS absent m both 
cases) including: 
1. Leber's disease 
2. Behr' s syndrome 
H. nutritional neuropathies. VFs are usually central or cecocentral. 
Discs are usually not cupped. 
I. cranial arteritis 
J. emboli 
K. carotid artery disease 
L. atrophy. When degree of optic disc pallor exceeds dimensions of 
physical cuppmg, atrophy unrelated to glaucoma must be 
suspected. 
See appendix 3 for differentiating progressive from non-progressive 
types of conditions that may mimic NTG. When NTG is still suspect, 
the following sub-classifications might prove useful [also see 
appendix 1] 
I) Focal ischemic NTG (FINTG) characterized by cuppmg m the 
vertical direction and steep sided. 
2) Senile sclerotic NTG (SSNTG). Seen in cases of cuppmg 
prominently associated with peripapillary changes due to aging. 
Recognized by a pale, sloping cup that has a moth-eaten 
appearance, peripapillary atrophy and choroidal sclerosis. 
3) Myopic NTG the typical features are an obliquely implanted disc 
with shallow cup and myopic crescent. Patients tend to be younger 
and 80% show visual field progression within 10 years (1 ). 
4) Miscellaneous NTG. Includes those cases not sub classified m one 
of the other subgroups. This may include a vasospastic group. 
C. MANAGEMENT OF NORMAL TENSION GLAUCOMA 
The mode of management practiced depends greatly on the 
clinician's level of understanding and the available treatment options 
permitted by the state. As a primary care practitioner, it 1s 
important to work with other health professionals m order to 
provide the most complete treatment available. 
1. Basis for Treatment 
Before any treatment and management of the condition is executed, 
it is crucial to diagnose the underlying problem at hand, thus, a full 
vascular work-up is advised. Once the diagnosis of NTG is made, a 
baseline pre-treatment pressure range is needed in order to estimate 
a reasonable target pressure. For example, if a patient's pressures 
are consistently in the mid to high teens, pressure reduction to low 
teens would be suitable. Some authors feel that the reduction in 
baseline pressure may not be a necessary goal for treatment with 
medications (5). To weigh the benefits of treatment versus no 
treatment, repeated diurnal pressure measurements are useful. lOP 
should be measured initially every month at various times of the day 
so as to account for diurnal fluctuations and then every three months 
for follow-up care. 
Upon obtaining the target pressure, medical treatment is the first 
line of defense against further damage, keeping In mind the 
importance of increasing choroidal, retinal, and optic nerve blood 
flow in addition to lowering the lOP. 
Once there is evidence of progressing disc or visual field damage and 
treatment begins, it is important to monitor any changes. Retinal 
nerve fiber layer examination can be important in the follow-up of 
glaucoma. For proper management, a Nerve Fiber Analyzer can 
provide optometrists with valuable information about the thickness 
of the nerve fiber layer to detect any; subtle glaucomatous 
changes(25). Visual fields should be assessed monthly with 
computerized instrument using standard procedures (7). 
Photography of the optic disc is recommended to note any changes 
in the back of the eye. In addition to the conventional methods of 
taking photos, a new sophisticated instrumentation is now available 
to take red-free optic nerve head photos, essential for exammmg any 
optic nerve fiber dropout and clefting (25). Other instruments are 
also available to create a automated stereoscopic evaluation of the 
disc. For example, the PAR IS-2000 from Toopcon can calculate a 
statistical profile that includes C/D ratio, nm area, cup volume, and 
can determine data from ONH pallor (8). Another method of 
collecting images needed for proper management and treatment can 
be done with the use of confocal scanning laser ophthalmoscopes and 
laser tomographs which gather information from the vitreous to the 
choroid so as to create a 3D image of the nerve head. 
2. Available Treatment Options 
a. Medical 
There is disagreement over which medication should be used as the 
first-line of defense against NTG. Others feel that dorzolamide 1s a 
better choice because beta blockers are vasoconstrictive and may 
contribute to optic nerve damage (27). Some researchers suggest 
that the best initial treatment is with a selective beta-blocker such as 
betaxolol (26) or miotics (5). Although miotics are quite effective m 
lowering lOP, traditionally there are a lot of side effects associated 
with their administration. Frequent complaints include mwsts, 
stinging, and refractive shift. Common miotics are pilocarpine and 
carbachol. 
According to Hitchings, if visual field loss persists even after lOP has 
been lowered, then calcium channel antagonists (nifedipine or 
nimodipine) or an angiotensin inhibitor such as lisinopril should be 
considered for long-term treatment. Flammer and Kitazawa have 
shown that NTG patients show improvement in visual field after 
taking nifedipine a peripherally active calcium channel blocker (29). 
Results showed that nifedipine is beneficial in the routine treatment 
of NTG patients. Gasper et al. (3) studied the effects of magnesium, a 
physiologic calcium channel blocker, on NTG patients and found that 
it improved the peripheral circulation and showed a positive effect 
on visual field in those patients with vasospasm m addition to their 
glaucoma. Studies have indicated that systemic calcium channel 
blockers may be helpful for NTG patients (3 ). 
Adrenergic agonists such as epinephrine should be avoided in NTG 
patients since it has been shown that they reduce the blood flow in 
the optic nerve. Some clinicians have theorized that these vasoactive 
drugs may cause more harm than good for NTG patients. 
Antiserotonin agents such as nastidrofuryl (Praxilen), is another drug 
with a promising future in the treatment of NTG (5). 
b. Laser 
If pharmaceutical therapy fails to decrease the lOP to optimal levels, 
then, laser trabeculoplasty may be an option. Some clinicians report 
successful reduction of lOP with argon laser therapy whereas others 
have not (5). 
c. Surgery 
Despite medical and laser therapy some individuals with NTG 
continue to illustrate optic nerve and field loss with no significant 
changes m the lOP. In such cases, filtering surgery becomes an 
alternative. Successful results with filtration surgery has been 
reported (5). Hitchings (7) studied six LTG patients who had one eye 
untreated and the other surgically treated to lower the lOP. It was 
found that the rate of field loss between the two eyes was the same. 
Therefore, a clinician must try all other treatment modalities before 
surgery IS recommended. 
3. Patient Education 
Last but not least, patient compliance is critical. Motivation is always 
a problem because no visible changes are noted by the patient. 
Therefore, it is important to present a clear definition of the disease 
and make sure that the patient has a good understanding of the 
nature of the problem. Our primary goal is to educate the patients 
and to optimize what 1s available to us in vanous forms so that the 
best care is received. 
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Differential Diagnosis into progressive 
and non-progressive conditions that may mimic 
NTG 
Appendix 3 
Non-progressive 
burnt-out openangle 
glaucoma 
burntout corticosteroid 
glaucoma 
burnt-out pigmentary 
glaucoma 
hemodynamic shock 
resolved AION 
resolved elevated 
episcleral venous 
pressure (e.g. thyroid 
exophthalmopathy 
optic nerve pit 
coloboma of the disc 
tilted disc 
optic nerve head drusen 
Progressive 
vena cava obstruction 
cavernous sinus fistula 
orbital varices 
Sturge-Weber syndrome 
Drug-induced atrophy 
POAG with large 
diurnal variations 
Intermittent (creeping) angle 
closure glaucoma 
pituitary tumor 
Schnabel's (cavernous or 
lacunar) 
optic atrophy 
visual field 
type of visual field defect 
field loss relative to 
duration 
affected hemishcre 
proximity to fixation 
margin of defect 
depth of depression 
uniformity of defect 
unaffected visualfield 
laterality 
Comparison in visual field 
changes 
between NTG and POAG ('\) 
Appendix 2 
NTG 
nerve fiber bundle defect (arcuate 
scotoma) 
more severe? 
superior hcmifield 
commonly with 10 
steepsided 
deep 
tend to uniformity? 
thresholds relatively normal 
may be unilateral but mostly bilateral 
POAG 
nerve fiber bundle defect (arcuate 
scotoma) 
less severe? 
superior=inferior hemifield most 
common 
commonly 10-15 from fixation 
steep or sloping margins 
Jess deeprelative to duration 
less uniform over defects? 
increase of threshold in remaining 
field 
unilateral presentation uncommon 
SSNTG 
sloping and less extensive 
common 
pale with moth eaten 
apperance 
extremely common 
common 
poor chorodial circulation 
slower venous filling time 
Optic nerve features in 
various forms of NTG 
MNTG 
oblique and shallow 
uncommon 
more local 
poor chorodial 
circulation 
slower venous filling 
time 
POAG 
sloping and more extensive 
uncommon 
occasional 
baring is common 
at vertical poles and more 
diffuse 
slower venous filling time 
FEATURE 
cupping 
disc hemorrhages 
pall or 
peripapillary atrophy 
vessels 
location of rim damage 
choroidal sclerosis 
fluorescein angiography 
Optic nerve features in 
various forms of NTG 
Appendix 1 
mise NTG 
steep 
frequent and recurrent 
common 
baring is common 
focal as inferior temporal notch 
FINTG 
steep 
common 
more local 
vertical direction 
infrequent 
